Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model

dc.contributor.authorPais, Helio
dc.contributor.authorRuggero, Katia
dc.contributor.authorZhang, Jing
dc.contributor.authorAl-Assar, Osama
dc.contributor.authorBery, Nicolas
dc.contributor.authorBhuller, Ravneet
dc.contributor.authorWeston, Victoria
dc.contributor.authorKearns, Pamela R.
dc.contributor.authorMecucci, Cristina
dc.contributor.authorMiller, Ami
dc.contributor.authorRabbitts, Terence H.
dc.date.accessioned2020-10-28T08:19:35Z
dc.date.available2020-10-28T08:19:35Z
dc.date.issued2019-04-08
dc.date.updated2020-10-26T09:22:11Z
dc.description.abstractThe surfaceome is critical because surface proteins provide a gateway for internal signals and transfer of molecules into cells, and surfaceome differences can influence therapy response. We have used a surfaceome analysis method, based on comparing RNA-seq data between normal and abnormal cells (Surfaceome DataBase Mining or Surfaceome DBM), to identify sets of upregulated cell surface protein mRNAs in an LMO2-mediated T-ALL mouse model and corroborated by protein detection using antibodies. In this model the leukemia initiating cells (LICs) comprise pre-leukaemic, differentiation inhibited thymocytes allowing us to provide a profile of the LIC surfaceome in which GPR56, CD53 and CD59a are co-expressed with CD25. Implementation of cell surface interaction assays demonstrates fluid interaction of surface proteins and CD25 is only internalized when co-localized with other proteins. The Surfaceome DBM approach to analyse cancer cell surfaceomes is a way to find targetable surface biomarkers for clinical conditions where RNA-seq data from normal and abnormal cell are available.
dc.format.extent16 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid30962539
dc.identifier.urihttps://hdl.handle.net/2445/171572
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41598-019-42214-w
dc.relation.ispartofScientific Reports, 2019-04-08, Vol. 9, num.5760
dc.relation.urihttps://doi.org/10.1038/s41598-019-42214-w
dc.rightscc by (c) Pais, Helio et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationMarcadors bioquímics
dc.subject.classificationLeucèmia
dc.subject.meshLeukemia
dc.subject.otherBiochemical markers
dc.titleSurfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
PaisH.pdf
Mida:
4.1 MB
Format:
Adobe Portable Document Format